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Abstract
Background: Growing evidence suggests that SALL4 plays a vital role in tumor progression and metastasis.
However, the molecular mechanism of SALL4 promoting esophageal squamous cell carcinoma (ESCC) remains to
be elucidated.
Methods: The gene and protein expression profiles- were examined by using quantitative real-time PCR,
immunohistochemistry and western blotting. Small hairpin RNA was used to evaluate the role of SALL4 both in cell
lines and in animal models. Cell proliferation, apoptosis and invasion were assessed by CCK8, flow cytometry and
transwell-matrigel assays. Sphere formation assay was used for cancer stem cell derivation and characterization.
Results: Our study showed that the transcription factor SALL4 was overexpressed in a majority of human ESCC
tissues and closely correlated with a poor outcome. We established the lentiviral system using short hairpin RNA to
knockdown SALL4 in TE7 and EC109 cells. Silencing of SALL4 inhibited the cell proliferation, induced apoptosis and
the G1 phase arrest in cell cycle, decreased the ability of migration/invasion, clonogenicity and stemness in vitro.
Besides, down-regulation of SALL4 enhanced the ESCC cells’ sensitivity to cisplatin. Xenograft tumor models
showed that silencing of SALL4 decreased the ability to form tumors in vivo. Furthermore, our study demonstrated
that SALL4 played a vital role in modulating the stemness of ESCC cells via Wnt/β-catenin signaling pathway and in
epithelial-mesenchymal transition.
Conclusions: Our results revealed that SALL4 might serve as a functional marker for ESCC cancer stem cell, a crucial
marker for prognosis and an attractive candidate for target therapy of ESCC.
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Background
Esophageal cancer is the sixth leading cause of cancer-
related death in the world and third in China [1, 2].
Esophageal squamous cell carcinoma (ESCC) is the
predominant subtype of esophagus cancer. Almost 90 %
of cases are squamous cell carcinomas in the highest risk
area of Asia, especially in Henan province [3, 4]. Due to
the lack of early detection, most of the patients are often
diagnosed with advanced disease, causing the prognosis
remains dismal and large probability of recurrent
disease. Recent data indicated that 5-year overall survival
was only 17 % in ESCC [5]. Thus, there is an urgent
need to explore the underlying molecular mechanisms
and the new potential treatment targets. Malignancies
arise from a small population of stem-cell-like cancer
cells. These cells are known as cancer stem cells (CSCs).
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CSCs were widely studied in various tumors and CSCs tar-
geted therapy could be a great help for ESCC treatment [6].
CSCs have high tumor-initiating, self-renewal and differen-
tiation ability. Moreover, CSCs are resistant to chemother-
apy and radiotherapy and responsible for cancer recurrence
and distant metastasis [7, 8]. Markers that identify CSCs
have been found in some tumors [9, 10]. However, the
candidate biomarkers in human ESCC are limited.
The sal-like protein 4 (SALL4) is a member of SALL
gene family. It was firstly cloned based on its sequence
homology to Drosophila spalt [11]. SALL4 acts as a C2H2
zinc-finger transcription factor, plays essential roles in
maintaining pluripotency and self-renewal of embryonic
and hematopoietic stem cells [12–14]. It’s also engaged in
maintaining stemness state and survival by forming a
SALL4, Oct4, Sox2 and Nanog transcription regulation
feedback loop [15, 16]. SALL4 was firstly described in
leukemogenesis, with constitutive expression in human
acute myeloid leukemia [17]. Subsequently, SALL4 ex-
pression has been found in various types of solid tumors,
including lung cancer, endometrial cancer, gastric cancer
and liver cancer [18–21].
Although emerging evidence reveals that SALL4 is in-
volved in carcinogenesis, the functional roles of SALL4 in
ESCC are still unknown. In this study, we aimed to under-
take a detailed analysis of SALL4 expression in ESCC and
explore its underlying mechanism. We further investi-
gated the function of SALL4 in ESCC in vitro and in vivo,
and characterized the role of SALL4 in regulating the
proliferation, apoptosis, cell cycle, migration, invasion, clo-
nogenicity and stemness of ESCC cells. Our studies also
suggested depletion of SALL4 induced a mesenchymal-
epithelial transition (MET) phenotype via Wnt/β-catenin
signaling pathway. Taken together, our studies indicate
that SALL4 plays a pivotal role during ESCC development
and progression and might serve as a potential target of
ESCC treatment.
Methods
Patients and tumor samples
One hundred and thirty-three paired ESCC tissues and
their matching adjacent non-cancerous tissues (located
more than 5 cm away from cancer tissues) were obtained
from The First Affiliated Hospital of Zhengzhou Univer-
sity. All patients were not received any therapeutic inter-
vention such as chemo- and radiotherapy. The samples
used in the study were approved by the ethics committee
of the First Affiliated Hospital of Zhengzhou University
and all patients provided written informed consent. The
clinicopathologic characteristics were evaluated including
gender, age, stage, histological grade, lymph nodes metas-
tasis and tumor invasion. The patients were staged
according to the TNM staging system and all samples
were confirmed by pathological analysis.
Cell culture and ESCC cell lines
Normal esophageal epithelium cell line Het-1a, human
ESCC cell lines TE1, TE7, EC1, EC109, EC9706, KYSE70
and KYSE450 were preserved in our laboratory and
maintained in RMPI 1640 (Hyclone, USA) supplemented
with 10 % fetal bovine serum (FBS, Hyclone, USA), 100
units/mL of penicillin, and 100 μg/ml of streptomycin at
37 °C, 5 % CO2 in a humidified incubator. Cells infected
with lentivirus were sorted by flow cytometry. Then cells
were harvested and cultured for subsequent functional
studies.
RNA extraction and quantitative real-time polymerase
chain reaction (PCR)
Total RNA was extracted from ESCC cells and tissues
with TRIzol reagend (Invitrogen Corporation, Carlsbad,
CA) according to manufacturer’s instructions. The
concentration and purity of RNA were detected using
NanoDrop 2000 (Thermo Scientific). The First-strand
cDNA was synthesized from 1 μg of total RNA using
PrimeScript RT reagent Kit With gDNA Eraser (TaKaRa,
Japan). Quantitative real-time PCR was performed using
SYBR Premix Ex Taq II (TaKaRa, Japan) in Agilent
Mx3005P. Each experiment was performed in triplicate.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as an endogenous control for normalization.
Immunohistochemistry
Immunohistochemistry was performed according to stand-
ard protocols. SALL4 expression was scored according to
the percentage of positive stained-tumor cells and the
intensity of staining for SALL4. The percentage scoring of
immunoreactive tumor cells was as follows: 0 (<10 %), 1
(10–40 %), 2 (40–70 %) and 3 (>70 %). The staining inten-
sity was visually scored and stratified as follows: 0 (nega-
tive), 1 (yellowish), 2 (light brown), 3 (dark brown). A final
immunoreactivity score was obtained for each case by
multiplying the percentage and the intensity score. High
SALL4 group had scores equal to or exceeded the median
level of expression, whereas low SALL4 group with scores
less than the medium level of SALL4 expression. In
addition, SALL4 expression in ESCC tissues was scored by
a pathologist and two researchers independently.
Western blotting
Total cell proteins were extracted in RIPA lysis buffer.
The protein concentration was determined by using
BCA method (Biyuntian, Jiangsu, China). Equal amount
of proteins were loaded on a 10 % SDS-PAGE (sodium
dodecyl sulfate-polyacrylamide gel electrophoresis) gel.
Following electrophoresis, the proteins were blotted to a
PVDF membrane. The membrane was blocked in 5 %
non-fat milk and then incubated with primary antibodies
overnight at 4 °C and secondary antibody reactions for
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2 h at 37 °C. Sources of primary antibodies were: anti-
SALL4, anti-Vimentin and anti-E-cadherin (Abcam,
Cambridge, MA, USA), anti-β-catenin, anti-wnt3a, anti-
β-actin antibodies (Cell Signaling Technology, USA)
Lentiviral generation and cell sorting
Stably knockdown of SALL4 in TE7 and EC109 cells by
shRNA was achieved using pGLV-H1-GFP + Puro vector
plasmid purchased from GenePharma (GenePharma,
Shanghai, China). For viral transductions, 500 μL of the
pGLV-H1-shControl or pGLV-H1-shSALL4 lentiviruses
were transfected with TE7 cells, and the expression of
SALL4 was confirmed by real-time RT-PCR and western
blotting. All the inserted sequences were confirmed by
DNA sequencing. After 48 h, the transfected cells were
sorted by flow cytometry (Beckman MoFlo XDP, Brea,
CA, USA) according to the expression of green fluores-
cent protein (GFP).
Cell proliferation assay
The proliferation of TE7 and EC109 cells was examined
via CCK-8 (Dojindo, Japan) assay. Briefly, cells were
counted at 1000 cells in 100 μL medium per well plated
in 96-well plates and grown under normal conditions.
Then for 5 d, every 24 h a batch of cells were stained
with 10 μL of CCK-8 reagent at 37 °C for 2 h, absorb-
ance at 450 nm was measured to calculate the number
of viable cells. All assays were performed in quadrupli-
cate. The data were expressed as the mean values ± SD
of 4 wells per treatment.
Flow cytometrical evaluation of apoptosis
After 48 h of transfection with scramble shRNA and
shSALL4, TE7 and EC109 cells were harvested and
washed with ice-cold PBS twice. And then cells were
suspended in the Annexin V-binding buffer to a final
concentration of 106 cells/mL. Thereafter, cells were
incubated with AlexaFluor647 AnnexinV (Biolegend,
USA) for 15 min at 4 °C in the dark, and PI (Sigma,
USA) was added. Samples were immediately analyzed by
flow cytometry (BD FACSCantoll).
Cell cycle analysis
Cells plated onto the 6-well plate were trypsinized with-
out EDTA and washed with pre-cooling normal saline.
Then the cells were fixed by 70 % alcohol overnight at
4 °C. Cell cycle analysis was performed using RNaseA
and PI staining by flow cytometry. The cells in G0/G1, S
and G2/M phases were measured using FlowJo software.
Transwell migration and invasion assays in vitro
Migration assay was performed by a filter of transwell
system (8.0 μm Pore Size, 24-well insert) and Matrigel
(BD, USA) was plated to the wells and used for invasion
assay. 5 × 104 cells with FBS-free media were added to
the upper chamber and 600 μL of medium with FBS was
added to the lower chamber. Then cells were incubated
under standard culture conditions for 24 h (migration
assay) or 48 h (invasion assay). Cells remaining on the
top of membrane were removed by using cotton swab
and the migrated or invaded tumor cells were stained by
0.1 % crystal violet solution for calculating analysis.
Colony-formation assay
Five hundred cells per well were seeded into 6-well plate
and incubated at 37 °C in a 5 % CO2 humidified incuba-
tor for 10 d. The medium was changed at 3 d intervals.
At the end of the assay, the cultures were fixed with 4 %
paraformaldehyde and stained with crystal violet.
Sphere formation assay
The sorted TE7 and EC109 cells were grown in DMEM/
F12 medium (Invitrogen Life Technologies) supplemented
with 4 μg/mL heparin (Sigma, St. Louis, MO, USA), 2 %
B27 (Gibco, Life Technologies, Carlsbad, CA, USA),
20 ng/mL basic fibroblast growth factor (bFGF) and
epidermal growth factor (EGF, both from PeproTech,
Rocky Hill, NJ, USA), 100 IU/mL penicillin and 100 μg/
mL streptomycin. Then they were seeded in 6-well ultra-
low cluster plates (Corning Costar, Corning, NY, USA).
After culturing for 14 d, the number of spheres was quan-
tified by using microscopy (Leica, Wetzlar, Germany).
Drug sensitivity assay
Cisplatin was purchased from Sigma. The sorted TE7
and EC109 cells were seeded at 3000 cells/well in 96-
well plate and treated with chemotherapeutic reagents in
quadruplicate. Cell viability was evaluated using CCK-8
assay following treatment with indicated dosages for
48 h, and the absorbance was measured at 450 nm using
Multiskan Mk3 (Thermo Fisher Scientific, San Jose, CA,
USA). The percentage of survival in treated cells was
normalized with untreated controls. The apoptosis was
analyzed by flow cytometry.
Animal model
To generate a subcutaneous xenograft mouse model, 10
female BALB/c nude mice (Vital River Laboratory Animal
Technology Co. Ltd, China) aged 5 weeks were randomly
divided into two groups (five mice/group). Both groups
received hypodermic injections of either scramble shRNA
or shSALL4 TE-7 cells (5 × 106 cells in 200 μL PBS). Mice
were inspected every 3 d and tumor growth was evaluated
by measuring the length and width of the tumor mass with
calipers. Then the mice were sacrificed at 30 d after inocu-
lation and solid tumors were removed and measured. The
tumor volume was calculated by the formula: (length ×
width2)/2. All animal procedures were conducted in
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accordance with the Guide for the Care and Use of Labora-
tory Animals, and were approved by the Institutional
Animal Care and Use committee of the First Affiliated
Hospital of Zhengzhou University.
Statistical analysis
Data were expressed as mean ± SD and analyzed using the
Student’s t-test or chi-squared test. Paired t-test was used
for paired samples. Overall survival curves were plotted
according to the Kaplan–Meier method. Statistical ana-
lyses were performed using GraphPad Prism 5 software
(GraphPad Software, La Jolla, CA, USA). P < 0.05 was
considered to indicate a statistically significant difference.
Results
The level of SALL4 expression is up-regulated in ESCC
tissues
To investigate the expression of SALL4 in ESCC, one hun-
dred and thirty-three paired ESCC tissues and adjacent
non-cancerous tissues were analyzed by real-time PCR.
The results showed that SALL4 expression in ESCC tissues
was significantly higher than that in the matched non-
cancerous tissues (P < 0.0001, Fig. 1a and b). Then, the cor-
relation between SALL4 expression and patients’ clinico-
pathological characteristics was evaluated (Table 1). ESCC
tissues with exceeded or equal to twofold of SALL4 mRNA
expression (compared to adjacent normal control) were
defined as the high group, while those with less than two-
fold of SALL4 mRNA expression were interpreted as the
low group. Among the 133 ESCC cases, 102 (76.7 %)
showed high level of SALL4 expression and 31 (23.3 %)
showed low level of SALL4 expression in cancer tissues.
Moreover, SALL4 expression was closely correlated with
the stage of tumor (P = 0.0477) and lymph node metastasis
(P = 0.0068). Particularly, 35 (92.1 %) of 38 ESCC patients
with lymph node metastasis showed high level of SALL4
expression. Our results reveal that SALL4 expression was
strongly correlated with lymph node metastasis and
advanced clinical stage.
We further detected SALL4 protein expression in ESCC
and adjoining normal tissues by immunohistochemistry.
In general, the results suggested that the intensity and per-
centage of SALL4 immunostaining in cancer tissues were
much stronger than those in adjacent non-cancerous
tissues (Fig. 1c). Meanwhile, our immunohistochemistry
results supported that patients with lymph node metasta-
sis and advanced tumor stages had a stronger expression
of SALL4 compared to those without lymph node metas-
tasis and with early tumor stages. Additionally, to examine
whether SALL4 expression was associated with poor prog-
nosis, the survival analysis was performed by using
Kaplan-Meier method. The 68 ESCC patients were
divided into high or low group according to the SALL4
expression scoring by using immunohistochemistry. The
Fig. 1 Expression of SALL4 in ESCC tissues. a and b Real-time PCR analysis of SALL4 mRNA expression in ESCC (T) and paired non-cancerous (N)
tissues (***P < 0.001). c Representative photomicrographs of immunohistochemical staining for SALL4 in ESCC tissues and adjacent normal tissues.
1-Negative staining, 2-Normal tissues, 3-Weak staining, 4-Strong staining. d The Kaplan-Meier curves for the overall survival in ESCC patients with
SALL4-low and SALL4-high expression (P = 0.0027). Original magnification: 400×
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results revealed that the overall survival probability of high
group was significantly lower than those of the low group
(P = 0.0027, Fig. 1d), the average survival time for SALL4
low expression group was 39.6 months, whereas the me-
dian survival time for SALL4 high expression group was
only 18.3 months, indicating that SALL4 could serve as a
potential prognostic marker for ESCC. Taken together,
our results indicate that SALL4 expression is closely cor-
related with tumor stage, lymph node metastasis and poor
survival in ESCC patients.
SALL4 depletion decreases cell viability by inhibiting
proliferation, triggering cell apoptosis and inducing cell
cycle arrest in vitro
To assess the biological functional role of SALL4 in
ESCC, we further explored the expression of SALL4 in
an immortalized esophageal epithelial cell line (Het1A)
and 7 ESCC cell lines (TE1, TE7, EC1, EC109, EC9706,
KYSE70 and KYSE450) by real-time PCR (Fig. 2a). Com-
pared with the normal epithelia cell line, all ESCC cell
lines showed different levels of elevation. The highest
and moderate SALL4 mRNA expression cell lines TE7
and EC109 were selected for further research.
To explore the functional role of SALL4 in ESCC cells,
we used a lentiviral system to generate stably SALL4
knockdown cell lines. Two short hairpin RNAs (shRNAs)
designated as scramble and shSALL4 were specially
designed and constructed. After transfection for 72 h, the
stably transfected TE7 and EC109 cells were sorted by
flow cytometry. After cultured for 2 weeks, the purities of
sorted scramble and shSALL4 cells of TE7 was 97.8 and
96.1 %, respectively, the purities of sorted EC109 cells
were 95.6 and 94.2 %. Real-time PCR and western blot
analysis were used to confirm the knockdown efficiency of
SALL4. The level of SALL4 mRNA expression was signifi-
cantly reduced in shSALL4 cells compared to that in
scramble cells (Fig. 2b). In addition, the suppressed
expression of SALL4 protein in both sorted TE7 and
EC109 cells was confirmed by using western-blot analysis
(Fig. 2c). The above results demonstrated that the expres-
sion of SALL4 could be down-regulated by shRNAs
specifically and effectively.
Furthermore, we analyzed the effect of shSALL4 on cell
growth and apoptosis of ESCC cells. To determine the
effect of down-regulation of SALL4 on cell proliferation,
we performed the CCK-8 assay. The results showed that
down-regulation of SALL4 significantly inhibited TE7 and
EC109 cells proliferation (Fig. 2d). The effect of SALL4
depletion on the apoptosis of ESCC cells using Annexin V
staining was further assessed. The percentages of Annexin
V-positive cells were much higher in shSALL4 groups
than that in scrambled groups (Fig. 2e). Then we investi-
gated how the cell cycle populations altered during the
apoptosis induced by the knockdown of SALL4. Cell cycle
distribution analysis demonstrated that the number of
cells was increased at G0/G1 phase and was decreased at
S phase in shSALL4 cells, suggesting that knockdown of
SALL4 induces typical cell cycle arrest at G0/G1 phase in
ESCC cells (Fig. 2f). Collectively, these data suggest that
the depletion of SALL4 inhibits cell proliferation, triggers
cell apoptosis and induces cell cycle arrest in vitro.
Silencing of SALL4 suppresses migration and invasion of
ESCC cells in vitro
Metastasis is a central problem during cancer therapeu-
tics, as our result has indicated that the SALL4 expres-
sion was notably associated with lymph node metastasis,
thereby we aimed to asses whether loss of SALL4 could
affect tumor migration and invasion ability. As shown in
Fig. 3a and b, stable knock-down of SALL4 remarkably
reduced the number of migrated and invaded cells to
the lower side of the membrane. In addition, the migra-
tion and invasion capacities of the scramble cells were
significantly greater than those of shSALL4 cells. These
results indicate that SALL4 plays an essential role in the
migration and invasion of ESCC.
Table 1 Association between clinicopathological factors and
SALL4 expression in ESCC patients
Parameters Number SALL4 expression P-value
High group Low group
Age
≥60 94 75 19 0.2594
<60 39 27 12
Gender
Male 87 70 17 0.1965
Female 46 32 14
Stage
I + IIa 92 66 26 0.0477*
IIb + III + IV 41 36 5
Tumor invasion
T1 + T2 64 46 18 0.2244
T3 69 56 13
Lymph node metastasis
N0 95 67 28 0.0068**
N1 + N2 38 35 3
Histological Grade




Poorly differentiated 22 21 1
* P <0.05, ** P <0.01
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Subsequently, the colony-formation assay was conducted.
The results showed that TE7 and EC109 cells transfected
with shSALL4 formed fewer colonies than that in control
cells (Fig. 3c and d), suggesting that silencing SALL4
inhibits the anchorage-independent growth of ESCC cells.
Taken together, these findings suggest that down-regulation
of SALL4 significantly impedes the migration and invasion
of ESCC cells in vitro.
SALL4 is necessary for the maintenance of CSC properties
like self-renewal and drug resistance
To further evaluate the role of SALL4 in maintenance of
CSC properties, the sphere-formation assay was performed.
After culturing for 14 days, the number and the size of
tumor-spheres in the scramble group was obviously higher
than that in the shSALL4 group (Fig. 4a), while EC109 cells
showed no sphere-forming capacity at both scramble and
Fig. 2 Silencing of SALL4 inhibits cell proliferation, induces apoptosis and arrests cell cycle in vitro. a Real-time PCR analysis of SALL4 expression
in Het1A, TE1, TE7, EC1, EC109, EC9706, KYSE70, KYSE450 cell lines. b The mRNA level of SALL4 was verified in sorted TE7 and EC109 cells after
transfection. c The protein level of SALL4 in sorted TE7 and EC109 cells was assessed by using Western blotting. β-actin was used as an internal
control. d Cell viability was evaluated at indicated time points using CCK8 assay. e Cell apoptosis was measured by flow cytometric analysis.
f Knock-down of SALL4 induced cell cycle arrest at G0/G1 phase. (*P < 0.05, **P < 0.01, ***P < 0.001)
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shSALL4 groups (data not shown). In addition, the mRNA
expression level of the stemness marker Sox2, Oct4, Nanog
were all down-regulated in shSALL4 group, which was con-
firmed by using RT-PCR (Fig. 4b).
The process of sphere-forming is intended to enrich
the potential CSC subpopulation, and then we character-
ized the expression of CSC-related markers in CSC-
enriched subpopulation. The expression of SALL4 and
Fig. 3 Silencing of SALL4 suppresses migration and invasion capabilities in vitro. a The migratory and invasive capabilities of TE7 and EC109
cells were evaluated by using transwell migration and invasion assay. Representative microscopic images of the bottom chamber were shown.
b The bar graphs represented the average number of migrated cells and invaded cells on the underside of the membrane. The cell colony was
decreased after transfection in both shSALL4 TE7 (c) and EC109 (d) cells. Colonies with >100 cells were quantified. Original magnification:
200×. (*P < 0.05, **P < 0.01, ***P < 0.001)
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CSC-related markers, including CD44, CD133 and
ALDH1 was analyzed in spheres and adherent cells
respectively. As shown in Fig. 4c, TE7 sphere-forming
cells were highly expressed these CSC-related markers
(CD44, CD133 and ALDH1) as well as SALL4 compared
to the adherent cells. Sphere formation can be consid-
ered as a way that enriches CSC-like cells, in our study
the expression of SALL4 was obviously increased in
spheres. Therefore, we hypothesize SALL4 might be a
potential CSC marker for ESCC. Moreover, lower
expression level of CSC-related markers (CD44, CD133
and ALDH1) was found in SALL4 knockdown cells
compared to that in control (Fig. 4d). These data provide
proof of the role of SALL4 as a functional marker for
Fig. 4 SALL4 is necessary for the maintenance of CSC properties. a Bright-field microscopy images of spheres generated from scramble and shSALL4 TE7
cells after the sphere-formation assay. Original magnification: 200×. b The expression of stemness-related markers (Sox2, Oct4, Nanog) was down-regulated
in shSALL4 cells compared with scramble cells in TE7. c The expression of CSC markers SALL4, CD44, CD133 and ALDH1 were up-regulated in TE7 spheres
than control adherent cells. d Real-time PCR showing CD44, CD133 and ALDH1 in spheres generated from scramble and shSALL4 TE7 cells. e The
sensitivity of shSALL4 TE7 cells to cisplatin was increased in a concentration-dependent manner compared with scramble cells. f The apoptosis rate
was enhanced in shSALL4 TE7 cells treated with 10 μg/mL cisplatin. (*P< 0.05, **P< 0.01, ***P< 0.001)
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CSCs and a regulator for the maintenance of self-
renewal properties in ESCC.
Cisplatin resistance is inevitable in the process of cancer
treatment and remains to be solved. Recent study showed
that the existence of CSCs was responsible for chemothera-
peutic failure [22]. Besides, cisplatin resistance is an
impenetrable hurdle in ESCC patients. To investigate the
role of SALL4 in contributing to drug resistance, we further
explored whether SALL4 silencing could affect the sensitiv-
ity of TE7 cells to cisplatin treatment. Scramble and
shSALL4 TE7 cells were treated with different concentra-
tions of cisplatin, respectively. After 48 h, the CCK-8 assays
showed that knockdown of SALL4 decreased cisplatin
resistance and increased drug sensitivity in a dose-
dependent manner (Fig. 4e). To further investigate whether
cisplatin could also induce apoptosis in TE7 cells, apoptosis
assay was performed using Annexin-V by Flow Cytometry
analysis, and the results showed that knockdown of SALL4
could significantly enhance the drug sensitivity to cisplatin
treatment and induced cell apoptosis (Fig. 4f). In summary,
our data indicate that down-regulation of SALL4 increases
the drug sensitivity of ESCC cells to cisplatin. These find-
ings could be explored for future clinical application.
Down-regulation of SALL4 promotes mesenchymal-
epithelial transition (MET) via Wnt/β-catenin signaling
pathway during ESCC tumorigenisis
The acquisition of epithelial-mesenchymal transition
(EMT) phenotype and induction of CSC are interrelated
and contributes to metastasis of cancers. Therefore, we
further tested whether the down-regulation of SALL4
could have an effect on the development of EMT in ESCC
cells using real-time PCR and western blotting assay. The
results indicated that the mRNA and protein levels of
epithelial cell marker (E-cadherin) were significantly
increased. Conversely, the expression of mesenchymal cell
marker (Vimentin) was decreased in shSALL4 group
(Fig. 5a and b). All the data suggest that down-regulation
of SALL4 promotes MET and attenuates EMT in ESCC.
The Wnt/β-catenin signaling pathway is known to play
a vital role in driving the initiation of tumorigenisis and
tumor growth. Activation of Wnt/β-catenin pathway can
promote transcriptional changes in order to drive EMT
in cancer [23]. Thus, we detected the expression of
Wnt3a and β-catenin in TE7 cells with stable down-
regulation of SALL4 using real-time PCR and western
blotting analyses. Strikingly, our results showed that
knockdown of SALL4 remarkably decreased the expres-
sion of Wnt3a and β-catenin in both mRNA (Fig. 5c)
and protein level (Fig. 5d), suggesting that SALL4 could
activate the Wnt/β-catenin signaling pathway to drive
EMT in ESCC. In summary, our results uncover that si-
lencing of SALL4 promotes MET via Wnt/β-catenin sig-
naling pathway during ESCC tumorigenisis.
Knockdown of SALL4 inhibits tumor formation in vivo
To further investigate the influence of down-regulation
SALL4 on tumor growth in vivo, we subcutaneously
injected the scramble and shSALL4 TE7 cells into nude
mice to establish xenograft tumor models. Representa-
tive images of tumor size of scramble and shSALL4
groups were shown in Fig. 6a. Scramble cells formed
subcutaneous tumors earlier than shSALL4 TE7 cells. In
the scramble group, tumor nodule started to form at day
6 after injection, and the tumor incidence reached 100 %
at day 15 after injection. However, compared to the
scramble group, tumor nodule in shSALL4 group began
to form at day 12 and tumor incidence was only 80 %
after implantation (Fig. 6b). The tumors grew faster in
the scramble group, and the tumor weight was signifi-
cantly higher than that in the shSALL4 group (Fig. 6c
and d). The mean tumor volume in the scramble group
reached 430 mm3, but only 95 mm3 in the shSALL4
group at day 30 after implantation. Taken together, these
results suggest that knockdown of SALL4 reduces tumor
burden and inhibits tumor formation in vivo.
Discussion
SALL4 is expressed in fetal organs, including fetal livers,
diminished gradually during development of the embryo
and silenced in most of the adult tissues but re-expressed
in some solid tumors, germ cell tumors and leukemia. Al-
though aberrant activation of SALL4 has been observed in
several human malignancies, the potential molecular mech-
anisms of SALL4 in ESCC remain to be elucidated. Here
we reported that SALL4 was significantly up-regulated in
above half of the human ESCC tissues, our results were
consistent with a recent study on the expression of SALL4
in ESCC [24]. We observed a significant correlation be-
tween SALL4 expression and lymph node metastasis,
advanced clinical stage and poor survival rate in ESCC,
indicating that SALL4 might play a crucial role in ESCC
progression. On determining the functional role of SALL4
in ESCC, we provide the first evidence that SALL4 could
regulate ESCC cell proliferation, apoptosis, cell cycle, inva-
sion, migration, clonogenicity and stemness. Deng et al.
recently found that SALL4 expression was correlated with
the Ki67 and CA199 expression in Intrahepatic cholangio-
carcinoma (ICC) [25], these two factors are markers for
increased proliferation of cancer cells, which may explain
why SALL4 influences the proliferation of ESCC cells.
Accumulating evidence suggests that many solid tumors
contain a small subset of tumor cells known as CSCs [26],
which display stem cell characteristics, including self-
renewal and differentiation into a heterogeneous tumor
cell population consisting of progenitor cells and more
differentiated cancer cells [27, 28]. CSCs are responsible
for initiation, progression, recurrence, metastasis and
chemo-radiotherapy resistance and therefore considered
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Fig. 5 Down-regulation of SALL4 promotes mesenchymal-epithelial transition (MET) via Wnt/β-catenin signaling pathway during ESCC tumorigenisis.
The expression of epithelial cell marker (E-cadherin) was elevated, while mesenchymal cell marker (Vimentin) was decreased in TE7 shSALL4 cells compared
with scramble cells both in mRNA level (a) and protein level (b). The expression of the key molecules in Wnt/β-catenin pathway Wnt3a and β-catenin was
down-regulated determined by real-time PCR (c) and western blotting (d) after silencing of SALL4. (**P< 0.01, ***P< 0.001)
Fig. 6 Knock-down of SALL4 inhibits tumor formation in xenograft models in vivo. a Tumor volumes in mice injected with shSALL4 TE7 cells were
remarkably smaller than the scramble group. Both tumor incidence (b) and tumor weight (c) were decreased in mice transplanted with shSALL4 TE7
cells compared with those injected with scramble cells. Tumor growth (d) was inhibited in mice transplanted with shSALL4 TE7 cells. (**P < 0.01)
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to be an ideal target for tumor eradication [7, 10]. CSCs
have also been identified by their ability to form tumor-
spheres in serum-free medium containing specific growth
factors [29]. However, the reports of CSC markers in
ESCC are quite limited. Recent studies demonstrated
CD271 and ALDH1 served as CSC markers in ESCC [30,
31]. In this study, we found that SALL4 was related to
cancer stemness features, such as colony ability, chemore-
sistance and EMT phenotype. Here, a strong correlation
between thesphere-forming capacity and SALL4 expres-
sion level was discovered and the expression of SALL4
was remarkably increased in spheres. Moreover, knock-
down of SALL4 abolished sphere formation capacity and
decreased expression of CSC markers, such as CD44,
CD133 and ALDH1 in TE7 cells. It has been reported that
SALL4, combined with Sox2, Oct4 and Nanog, plays a
pivotal role in maintaining the stemness of embryonic
stem cells (ESC)/pluripotent stem cells. As an up-stream
regulator, SALL4 could activate the expression of SOX2,
Oct4 and Nanog, meanwhile, these proteins can form a
transcriptional feedback network to control the develop-
ment of ESCs [15, 16, 32]. Our results showed that
shRNA-mediated SALL4 inhibition induced the loss of
stemness in ESCC cells through decreasing the expression
levels of Sox2, Oct4 and Nanog, which was in agreement
with previous studies. CSC is considered to be responsible
for drug resistance in cancer [8]. Here, we found that
knockdown of SALL4 in TE7 cells could increase the sen-
sitivity to cisplatin in a dose-dependent manner. This re-
sult suggests that SALL4 could be a potential target for
ESCC therapy. Inhibition of SALL4 may efficiently eradi-
cate CSCs in ESCC, which benefit patients with chemori-
sistance and improve their prognosis. With all findings
taken together, we hypothesize SALL4 expression contrib-
utes to the stemness in ESCC and SALL4 could serve as a
functional CSC marker for ESCC.
EMT plays crucial roles during embryonic development,
tumor metastasis and invasion and is one of the major mo-
lecular mechanisms through which invasion and metastasis
are promoted during the oncogenic process [33, 34]. In the
present study, we showed that shRNA-induced SALL4
silencing significantly restricted ESCC cell migration and
invasion. Besides, shRNA-induced SALL4 inhibited EMT
process by elevating the expression of epithelial marker E-
cadherin and reducing the expression of mesenchymal
marker Vimentin, suggesting that induction of MET may
be, at least partially, responsible for the decreased invasion
capacities of ESCC. Furthermore, it is well-known that
cancer cells undergoing EMT share the properties of stem
cell-like cells [35], which could indicate SALL4 as a CSC
marker in ESCC. Wnt/β-catenin signaling pathway plays a
critical role in regulating the activity of CSCs in various
cancers and contributes to the maintenance of the CSC
population [36, 37]. Activation of Wnt/β-catenin signaling
pathway has been implicated in stem cell self-renewal,
maintenance and differentiation [38, 39]. Ma et al. showed
that SALL4 could bind to β-catenin in vitro and synergistic-
ally enhanced the Wnt/β-catenin pathway in human acute
myeloid leukemia (AML) [17]. Shuai et al. found that Wnt/
β-catenin pathway downstream target genes c-Myc and
Cyclin D1 were activated and were closely correlated with
SALL4 expression in Myelodysplastic syndromes (MDS)
patients [40]. Hao et al. observed that SALL4 and β-catenin
co-located in the nucleus and cytoplasm and interacted in
colorectal cancer (CRC) [41]. However, no further experi-
ments were carried out to illuminate the relationship be-
tween SALL4 and Wnt/β-catenin pathway in solid tumors.
Our findings have demonstrated that SALL4 triggers the
Wnt/β-catenin signaling pathway and shRNA-induced
SALL4 inhibition can decrease Wnt3a and β-catenin ex-
pression at both mRNA and protein levels, suggesting tar-
geting SALL4 may be a promising new strategy to block
Wnt/β-catenin signaling pathway and EMT to prevent
tumor metastasis in ESCC. Thus, targeting Wnt/β-catenin
pathway potentially represents a promising therapeutic
approach for the treatment of ESCC. To the best of our
knowledge, this is the first report that SALL4 regulates the
expression of Wnt3a, a Wnt protein that activates the
canonical Wnt pathway. It has been reported that Wnt3a is
responsible for stimulating tumor progression in glioblast-
oma, prostate cancer and colon cancer [42–44]. Once
SALL4 was activated, it may trigger downstream target
gene Wnt3a to promote tumor progress and metastasis.
Though our study revealed the important role of SALL4 in
regulating the expression of Wnt3a, the specific mechanism
in this process remains unclear. In future studies, we will
investigate whether SALL4 could bind Wnt3a directly or
there is a crucial molecule between SALL4 and Wnt3a
regulation, and the role of Wnt3a in ESCC.
Conclusions
In summary, our study shows that aberrantly activated
SALL4 may contribute to esophageal tumorigenesis by
promoting malignant proliferation and inhibiting cell
apoptosis, regulating ESCC cell migration, invasion and
cell cycle. Besides, SALL4 expression activates Wnt/β-
catenin pathway, uncovering a mechanism underlying
EMT in ESCC. However, the specific mechanisms driv-
ing aberrant SALL4 expression in ESCC remain to be
further elucidated. Taken together, we propose that
SALL4 would be a functional CSC marker, a crucial
marker for prognosis and an attractive candidate for
target therapy of ESCC.
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